Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics (NASDAQ: INKT) will present Phase II data for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer at AACR 2026.
The investigator-initiated trial at Memorial Sloan Kettering evaluates immune reprogramming and treatment sequencing in checkpoint-refractory GEC; presentation is April 20, 2026, Poster Section 52, Abstract CT166.
MiNK Therapeutics (NASDAQ: INKT) announced that an abstract on its investigational allogeneic iNKT cell therapy agenT-797 was accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 11-15, 2026, in Boston.
Presenter Terese C. Hammond, MD, will present data titled "AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS." Session timing and poster location will be posted on the ASGCT conference program website in mid-April.
MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.
Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.
MiNK Therapeutics (NASDAQ: INKT) reported Q4 and full‑year 2025 results and highlighted multiple 2026 clinical catalysts. Key facts: cash $13.4M at year‑end, an additional $3.0M raised post‑year, net loss $12.5M for FY2025, and advancing Phase 2 ARDS and GVHD programs with near‑term readouts.
Non‑dilutive funding includes a $1.1M C‑Further collaboration, an NIH NIAID STTR grant, and the Mary Gooze award, supporting clinical starts in 1H–2H 2026.
MiNK Therapeutics (NASDAQ: INKT) will report fourth quarter and full year 2025 financial results before market open on March 31, 2026 and host a conference call and webcast at 8:30 a.m. ET.
The company also highlighted platform expansion with a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers, citing non-dilutive funding and downstream commercial revenue potential.
MiNK Therapeutics (Nasdaq: INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.
The program receives up to ~$1.1 million in non-dilutive, aggregate funding for IND-enabling work and milestone-driven preclinical candidate nomination, plus a meaningful double-digit share of downstream commercial revenues; collaboration is non-exclusive.
C-Further unveiled its first two early-stage paediatric oncology programmes, CF-012 and CF-033, supported by an initial $40m (£30m) budget. CF-012 targets ETV6 for potential first-in-class inhibition in Ewing sarcoma. CF-033 is a PRAME-targeted allogeneic iNKT cell therapy developed with MiNK Therapeutics (NASDAQ: INKT) aimed at bone sarcoma, medulloblastoma and acute myeloid leukaemia. Projects will be advanced to preclinical candidate nomination subject to scientific milestones. Research partners include UVA Comprehensive Cancer Center, Dana-Farber, Mass General Brigham and University of Southampton. C-Further invites proposals with a submission deadline of 13 March 2026, and additional programmes are expected in 2026.
MiNK Therapeutics (Nasdaq: INKT) presented translational human lung data at Keystone Symposia (Feb 1–4, 2026) showing significant depletion of iNKT cells in lung-associated lymph nodes from end-stage idiopathic pulmonary fibrosis (IPF) patients.
Findings support a mechanistic role for iNKT insufficiency in advanced IPF and strengthen rationale for iNKT cell replenishment strategies to restore immune balance and support tissue repair in fibrotic lung disease.
MiNK Therapeutics (NASDAQ: INKT) and University of Wisconsin–Madison will initiate an investigator‑sponsored Phase 1 trial of allo‑iNKT cell therapy agenT‑797 to evaluate safety, tolerability, and preliminary efficacy for preventing graft‑versus‑host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation for high‑risk leukemias and other blood cancers.
The program is supported by two non‑dilutive awards: an NIAID STTR grant for preclinical development and a Mary Gooze Clinical Trial Award to fund enrollment, immune monitoring, and operations. AgenT‑797 is described as an off‑the‑shelf, HLA‑independent, lymphodepletion‑free donor‑derived iNKT therapy with prior favorable safety and immune‑modulating activity reported in solid tumors and ARDS.
MiNK Therapeutics (NASDAQ: INKT) on November 20, 2025 published preclinical data for MiNK-215, an allogeneic, IL-15–enhanced FAP-targeting CAR-iNKT designed to remove FAP+ cancer-associated fibroblasts and boost immune infiltration in solid tumors.
Key preclinical findings show MiNK-215: dismantles stromal barriers, selectively eliminates FAP+ fibroblasts, remodels the tumor microenvironment, activates dendritic cell and antigen-presentation pathways, repolarizes macrophages to a pro-inflammatory state, and enables deep tumor-specific T cell infiltration in refractory lung and MSS colorectal cancer models.
MiNK-215 is described as an off-the-shelf therapy manufacturable at scale to address solid tumors resistant to checkpoint inhibitors.